Thirty years of prostate screening data show the benefit keeps growing over time
Thirty-year results from the longest-running prostate cancer screening trial confirm mortality benefits that grow with time. Separate studies at the EAU26 congress show how risk-stratified MRI and the Stockholm3 blood test could cut unnecessary scans by up to 67%.